News
One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...
9d
Zacks.com on MSNHere's What to Expect From Pfizer's Non-Oncology Drugs in Q2 EarningsPFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.
Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...
Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...
Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of ...
Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...
14h
Zacks Investment Research on MSNBuy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 EarningsPfizer PFE will report its second-quarter 2025 earnings on Aug. 5, before market open. The Zacks Consensus Estimate for sales ...
Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris ...
Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent.
On July 30, 2025, Pfizer (PFE) saw its shares drop by 2.02%, with a trading volume hitting $0.86 billion and ranking 118th in ...
The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results